hVIVO acquires CRS Berlin, expands clinical trials footprint in Germany

PUBT · 1d ago
hVIVO acquires CRS Berlin, expands clinical trials footprint in Germany
  • hVIVO agreed to buy CRS Berlin, a Phase I/II clinical research unit focused on dermatology and women’s health.
  • Upfront consideration totals EUR 25,000; earnout set at 18% of annual revenue for 2026-2028, subject to minimum thresholds.
  • Management expects about EUR 6 million gross earnout cash; about EUR 4 million net after deductions for a EUR 2 million pension liability.
  • CRS Berlin posted 2025 revenue of EUR 10 million; unaudited EBITDA of EUR 300,000; net assets of EUR 100,000.
  • Contracted orderbook stood near EUR 10 million at June 30, 2026; deal expected to lift revenue and EBITDA in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. hVIVO plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270200OMX_____CNEWS_EN_GNW1001259535_en) on August 27, 2026, and is solely responsible for the information contained therein.